Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase II trial

Jamie E Chaft
Weill Cornell Medical College
G Alexander Patterson
Washington University School of Medicine in St. Louis
Saiama N Waqar
Washington University School of Medicine in St. Louis
et al.

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Recommended Citation
https://digitalcommons.wustl.edu/oa_4/504

Please let us know how this document benefits you.
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14–28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR ≥ 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.

The survival of patients with resectable non-small cell lung cancer (NSCLC) has not substantially improved since the establishment of adjuvant chemotherapy as standard treatment more than 20 years ago. Inhibitors of PD-1 or PD-L1 are approved for the treatment of advanced-stage NSCLC and resected stage II–III, PD-L1-expressing NSCLC. These agents have shown some benefit when given before surgery in small (n = 21–23) studies of patients with resectable NSCLC; however, the pathological response rates in these studies have wide confidence intervals (CIs) and predictive biomarkers of response remain unclear. The phase II Lung Cancer Mutation Consortium 3 (LCMC3) study was performed to evaluate the efficacy of neoadjuvant atezolizumab, a PD-L1 inhibitor, in a large population of treatment-naïve patients with resectable, stage IB–IIIB NSCLC. Prospective correlative studies were performed to elucidate potential predictors of treatment response and resistance.

Atezolizumab is hypothesized to enhance antitumor immunity by restoring the function of cytotoxic T cells, but the details of this mechanism in humans and the effects of atezolizumab on other immune cell populations are largely undefined. Because not all patients respond to PD-(L)1 inhibition, identifying biomarkers predictive of response and resistance may aid in treatment selection. Moreover, elucidating the mechanisms by which cancer cells evade antitumor immunity may inform rational combination therapies. To define the clinical and biological effects of neoadjuvant atezolizumab and to identify biomarkers predictive of response (or lack thereof), the LCMC3 study evaluated the immune environment pre- and post-treatment with atezolizumab and corre-
related these changes with the primary efficacy measure of MPR (Extended Data Fig. 1).

**Results**

**Patients.** Between 20 April 2017 and 3 February 2020, 181 patients with NSCLC were enrolled (Fig. 1). Baseline demographics and disease characteristics are summarized in Table 1 and Supplementary Table 1. A total of 171 (94%) patients received both doses of atezolizumab; 10 (6%) did not (due to 7 adverse events [AEs], 2 physician decisions and 1 withdrawal). The seven AEs leading to discontinuation of atezolizumab were infusion-related reaction (n = 2), pyrexia (n = 2), fatigue, diverticulitis and dyspnea (all n = 1). During the second infusion, 13 patients required dose interruption, 12 because of infusion-related reactions and 1 because of ongoing (non-worsening) cough and dyspnea. Of the 181 patients, 159 (88%) had surgery with curative intent; 22 (12%) did not have surgery, as detailed in Fig. 1.

**Efficacy.** Of the 159 patients who had surgery, 16 (10%) had tumors harboring EGFR mutations (exon 19 deletion, n = 8; exon 20 insertion, n = 1; L858R, n = 1) or ALK rearrangements (n = 6) and were excluded from the primary efficacy analysis. In the primary analysis population, the MPR rate was 20% (29 of 143; 95% CI 14–28%) and the pathological complete response (pCR) rate was 6% (8 of 143; 95% CI 3–11%) (Fig. 2a). The characteristics of patients with pCR are summarized in Supplementary Table 2. In subgroup analyses, the odds of MPR were higher in patients who were female or who had partial response as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, N1 disease or squamous histology (Supplementary Table 3). The secondary end point of MPR rate in patients with a PD-L1 tumor proportion score (TPS) of <1%, 1–49% and ≥50% at screening was 11% (6 of 53), 5% (1 of 20) and 33% (15 of 45), respectively (P = 0.01, two-sided Fisher’s exact test). In an analysis of data from 111 patients, baseline PD-L1 TPS was found to correlate significantly with pathological response (R = −0.37; P < 0.001). No tumor with EGFR or ALK alterations demonstrated radiographical response or MPR. Regarding radiographical responses in the 181 patients who received ≥1 dose of atezolizumab, 11 had partial responses (6%), 147 (81%) had stable disease, 13 (7%) had progressive disease (PD; local, n = 6; regional, n = 7) and 10 (6%) were not assessed.

Exome sequencing data from analysis of pre-treatment paired tumor and normal samples were available for 123 patients (44 squamous and 79 non-squamous) (Extended Data Fig. 2). The secondary end point of MPR rate in patients with tumor mutational burden <10, 10–15 and ≥16 mutations per Mb was 13% (8 of 60), 10% (1 of 10) and 33% (5 of 15), respectively (<10 versus 10–15, P = 1.00; <10 versus ≥16, P = 0.12; 10–15 versus ≥16, P = 0.34; two-sided Fisher’s exact test) (Extended Data Fig. 3a). STK11 mutations demonstrated a trend toward lesser pathological regression versus wild-type STK11, significantly in patients with co-mutation of KRAS and STK11 (Extended Data Fig. 3b). KEAP1 mutations were not associated with pathological response.

Adjuvant treatment is summarized in Fig. 1. The exploratory end points of median disease-free survival (DFS) and overall survival (OS) were not reached. The 3-year DFS and OS were 72% (95% CI 62–79%) and 80% (95% CI 71–87%), respectively. Survival by MPR status is presented in Fig. 2b–d. Survival by disease stage, adjuvant atezolizumab use and lymph node status is presented in Extended Data Fig. 4. The duration of DFS in the eight patients with pCR is presented in Supplementary Table 2.

**Safety.** Of the 181 patients in the safety-evaluable population, 97% experienced at least one AE during the neoadjuvant phase (up to 90 d after last dose of neoadjuvant atezolizumab), most commonly fatigue (39%) and procedural pain (29%) (Supplementary Table 4). The most frequent atezolizumab-related AE was fatigue (20%). Immune-related AEs were reported in 75 (41%) patients, most commonly increases in aspartate aminotransferase (9%, n = 16), alanine aminotransferase (8%, n = 15), maculopapular rash (8%, n = 15) and the pathological complete response (pCR) rate was 6% (8 of 143; 95% CI 3–11%) (Fig. 2a). The characteristics of patients with pCR are summarized in Supplementary Table 2. In subgroup analyses, the odds of MPR were higher in patients who were female or who had partial response as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, N1 disease or squamous histology (Supplementary Table 3). The secondary end point of MPR rate in patients with a PD-L1 tumor proportion score (TPS) of <1%, 1–49% and ≥50% at screening was 11% (6 of 53), 5% (1 of 20) and 33% (15 of 45), respectively (P = 0.01, two-sided Fisher’s exact test). In an analysis of data from 111 patients, baseline PD-L1 TPS was found to correlate significantly with pathological response (R = −0.37; P < 0.001). No tumor with EGFR or ALK alterations demonstrated radiographical response or MPR. Regarding radiographical responses in the 181 patients who received ≥1 dose of atezolizumab, 11 had partial responses (6%), 147 (81%) had stable disease, 13 (7%) had progressive disease (PD; local, n = 6; regional, n = 7) and 10 (6%) were not assessed.

Exome sequencing data from analysis of pre-treatment paired tumor and normal samples were available for 123 patients (44 squamous and 79 non-squamous) (Extended Data Fig. 2). The secondary end point of MPR rate in patients with tumor mutational burden <10, 10–15 and ≥16 mutations per Mb was 13% (8 of 60), 10% (1 of 10) and 33% (5 of 15), respectively (<10 versus 10–15, P = 1.00; <10 versus ≥16, P = 0.12; 10–15 versus ≥16, P = 0.34; two-sided Fisher’s exact test) (Extended Data Fig. 3a). STK11 mutations demonstrated a trend toward lesser pathological regression versus wild-type STK11, significantly in patients with co-mutation of KRAS and STK11 (Extended Data Fig. 3b). KEAP1 mutations were not associated with pathological response.

Adjuvant treatment is summarized in Fig. 1. The exploratory end points of median disease-free survival (DFS) and overall survival (OS) were not reached. The 3-year DFS and OS were 72% (95% CI 62–79%) and 80% (95% CI 71–87%), respectively. Survival by MPR status is presented in Fig. 2b–d. Survival by disease stage, adjuvant atezolizumab use and lymph node status is presented in Extended Data Fig. 4. The duration of DFS in the eight patients with pCR is presented in Supplementary Table 2.

**Safety.** Of the 181 patients in the safety-evaluable population, 97% experienced at least one AE during the neoadjuvant phase (up to 90 d after last dose of neoadjuvant atezolizumab), most commonly fatigue (39%) and procedural pain (29%) (Supplementary Table 4). The most frequent atezolizumab-related AE was fatigue (20%). Immune-related AEs were reported in 75 (41%) patients, most commonly increases in aspartate aminotransferase (9%, n = 16), alanine aminotransferase (8%, n = 15), maculopapular rash (8%, n = 15)
and infusion-related reaction (8%, n = 15). Among the 20 (11%) patients with a treatment-related grade ≥3 AE, pneumonitis (2%, n = 4) and pneumonia (2%, n = 3) were the most frequent. Three (2%) patients died during the neoadjuvant phase; only 1 death was treatment-related (pneumonitis) (Supplementary Table 4).

IMMUNOME. In exploratory analyses, 111 pre-treatment peripheral blood samples were evaluated via ten-color 60-marker flow cytometry (IMMUNOME) (Supplementary Table 5 and Extended Data Fig. 5). Samples were split into a training set (n = 57) to develop a predictive model for MPR and a test set 1 (n = 54) (Extended Data Fig. 2). The area under the curve (AUC) was 0.987 for the training set and 0.722 for test set 1; the addition of individual clinical parameters did not significantly improve the predictive power (Fig. 3, Extended Data Fig. 6 and Supplementary Table 6). The final multivariable GAM–LASSO (generalized additive model–least absolute shrinkage and selection operator) model consisted of 14 immune cell subsets in the pre-treatment peripheral blood that significantly correlated with MPR. Higher prevalence of non-T/non-natural killer (NK) cells expressing the immunoregulatory receptors immunoglobulin-like transcript 2 (ILT2), killer cell immunoglobulin-like receptor (KIR) 2DL1 (KIR2DL1), and KIR2DL2 and of NK group 2 member D (NKG2D)+ non-T/non-NK cells positively associated with MPR (Supplementary Table 7 details immune cell descriptions and effect sizes). Higher prevalence of NK and NK-like T cell subsets in the peripheral blood (several of which express inhibitory receptors such as ILT2, NKG2A and NKG2D), subsets of γ/δ T cells, γ/δ NK-like T cells, degranulated myeloid cells, and naive CD4+CD127−T cells inversely associated with MPR (Supplementary Table 7).

The ability of the final model to predict the probability of MPR was evaluated in test set 2, consisting of nine study participants with radiographical PD who were not included in the training set or test set 1. The mean probability of MPR was predicted to be 0.20 in the PD cohort, 0.11 in the non-MPR cohort and 0.43 in the MPR cohort (PD versus non-MPR, P = 0.11; PD versus MPR, P = 0.0035; non-MPR versus MPR, P < 0.0001) (Fig. 3 and Supplementary Table 8).

When comparing pre- and post-atezolizumab peripheral blood, non-T/non-NK cells expressing ILT2, KIR2DL1 and KIR2DL2, as well as NKG2D+ NKG2A+ CD94+ CD127− CD161+ NK-like T cells, activated CD8+ T cells, activated CD56−/CD16− NK cells and NKG2A+ NKG2D+ CD127+ T cells underwent significant expansion (Extended Data Fig. 7). NKG2D+ NKG2A+ CD94+ CD127+ CD161+ NK-like T cells, central memory CD4+ T cells, a subset of immature myeloid lineage cells and ILT2+ NKG2A+ KIR2DL2+ NK cells underwent significant contraction in atezolizumab-treated patients who experienced MPR. A predictive model using pre- and post-treatment peripheral blood samples was calculated, with an AUC in test set 1 of 0.726 (Supplementary Table 9).

Gene expression analysis of tumor tissue. To determine how the IMMUNOME observations from pre-treatment peripheral blood translate to the tumor microenvironment, we analyzed gene expression at the single-cell level in tumor tissue. Single-cell RNA-sequencing (scRNA-seq) data from 15 surgical tumor samples were analyzed in an exploratory fashion to assess cells expressing the markers of interest. In tumor tissue, NKG2A and KIRs, including KIR2DL1, were predominantly expressed on NK cells (Fig. 4 and Extended Data Fig. 8); these receptors were more highly expressed on a greater percentage of NK cells in patients with lesser pathological regression (Fig. 4). ILT2 in tumor tissue, by contrast, was expressed to only a small extent on NK cells and was instead predominantly expressed on dendritic cells (DCs), macrophages and monocytes. PD-L1 was mainly expressed on DCs and common myeloid progenitor cells and to a lesser extent in tumor tissue (Fig. 4 and Extended Data Fig. 9).

Bulk RNA-seq data were available for 54 patients at baseline and 44 patients at surgery. In exploratory analyses, ILT2 and PD-L1 transcripts in the tumor sample assessed via bulk RNA-seq were significantly associated with pathological response in non-squamous tumors at baseline and surgery (Extended Data Fig. 10).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline demographics and disease characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n = 181)</td>
<td></td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td>65.0 (37–83)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td>93 (51)</td>
</tr>
<tr>
<td><strong>White</strong></td>
<td>145 (81)</td>
</tr>
<tr>
<td><strong>Black/African American</strong></td>
<td>13 (7)</td>
</tr>
<tr>
<td><strong>Asian</strong></td>
<td>9 (5)</td>
</tr>
<tr>
<td><strong>Unknown</strong></td>
<td>12 (7)</td>
</tr>
<tr>
<td><strong>ECOG performance status score, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>104 (57)</td>
</tr>
<tr>
<td>1</td>
<td>77 (43)</td>
</tr>
<tr>
<td><strong>Clinical stage, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>IB</td>
<td>18 (10)</td>
</tr>
<tr>
<td>IIA</td>
<td>16 (9)</td>
</tr>
<tr>
<td>IIB</td>
<td>55 (30)</td>
</tr>
<tr>
<td>IIIA</td>
<td>70 (39)</td>
</tr>
<tr>
<td>IIB*</td>
<td>22 (12)</td>
</tr>
<tr>
<td><strong>Histology, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Non-squamous</td>
<td>112 (62)</td>
</tr>
<tr>
<td>Squamous</td>
<td>69 (38)</td>
</tr>
<tr>
<td><strong>History of tobacco use, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>18 (10)</td>
</tr>
<tr>
<td>Current</td>
<td>35 (19)</td>
</tr>
<tr>
<td>Former</td>
<td>128 (71)</td>
</tr>
<tr>
<td><strong>Median pack-years, n (range)</strong></td>
<td>22.75 (0–162.0)</td>
</tr>
<tr>
<td><strong>PD-L1 TPS, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;1%</td>
<td>69 (38)</td>
</tr>
<tr>
<td>1–49%</td>
<td>28 (15)</td>
</tr>
<tr>
<td>≥50%</td>
<td>49 (27)</td>
</tr>
<tr>
<td>Unknown</td>
<td>35 (19)</td>
</tr>
<tr>
<td><strong>EGFR mutation, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>11 (6)</td>
</tr>
<tr>
<td>Negative</td>
<td>154 (85)</td>
</tr>
<tr>
<td>Unknown</td>
<td>16 (9)</td>
</tr>
<tr>
<td><strong>ALK rearrangement, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Negative</td>
<td>162 (90)</td>
</tr>
<tr>
<td>Unknown</td>
<td>13 (7)</td>
</tr>
</tbody>
</table>

ALK, anaplastic lymphoma kinase; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PD-L1, programmed death-ligand 1; TPS, tumor proportion score. *Select IIIB includes T3N2 or T4 (by size criteria, not by mediastinal invasion), per the American Joint Committee on Cancer Staging System (8th edition). **PD-L1 status was centrally determined by immunohistochemistry using the Dako PD-L1 (22C3) assay. The large number of patients with ‘unknown’ PD-L1 status was attributable to missing samples and failed testing. *Determined either locally or centrally from screening tissue (when adequate) or resected tumor tissue. **EGFR status was unknown in 16 patients (non-squamous, n = 5; squamous, n = 11). **ALK rearrangement status was unknown in 13 patients (non-squamous, n = 5; squamous, n = 8).
This phase II LCMC3 study of neoadjuvant atezolizumab, the largest study of preoperative checkpoint inhibitor monotherapy in early-stage NSCLC to date, met its primary end point with an MPR rate of 20% (6% pCR) in primary tumors from patients with resectable stage IB–IIIB NSCLC. Neoadjuvant atezolizumab was well tolerated, with a low incidence of treatment-related grade ≥3 AEs. There was only one treatment-related death (immune-mediated pneumonitis), the onset of which occurred 1 month after surgery; the patient died despite optimal medical management. The composite perioperative mortality rate in LCMC3 was equivalent to that of neoadjuvant chemotherapy and of surgery without chemotherapy5. Overall, the safety profile was consistent with that observed in advanced disease6–8. Biomarkers predictive of drug toxicity remain an unmet need. Despite a high-risk population, including approximately half of patients with clinical stage III disease, 88% of patients had planned surgery. Median DFS and OS were not reached, with an encouraging 3-year OS rate of 80%.

MPR was selected as the primary end point for this study to provide reasonable comparison to historical studies of neoadjuvant chemotherapy, in which MPR rates of 15–22% have been reported, rather than single-digit pCR rates9,10. These response rates have recently been substantiated in the randomized chemotherapy arm of CheckMate 816, reporting an MPR rate of 9% and pCR rate of 2%11. Small studies of neoadjuvant nivolumab monotherapy have demonstrated MPR rates of 22–45%12,13. Although MPR rates of 57–83% following neoadjuvant chemoimmunotherapy have recently been reported12,13, the addition of chemotherapy may confound the interpretation of immune predictors. Moreover, the results of these small studies have large confidence intervals. Larger

Discussion
This phase II LCMC3 study of neoadjuvant atezolizumab, the largest study of preoperative checkpoint inhibitor monotherapy in early-stage NSCLC to date, met its primary end point with an MPR rate of 20% (6% pCR) in primary tumors from patients with resectable stage IB–IIIB NSCLC. Neoadjuvant atezolizumab was well tolerated, with a low incidence of treatment-related grade ≥3 AEs. There was only one treatment-related death (immune-mediated pneumonitis), the onset of which occurred 1 month after surgery; the patient died despite optimal medical management. The composite perioperative mortality rate in LCMC3 was equivalent to that of neoadjuvant chemotherapy and of surgery without chemotherapy5. Overall, the safety profile was consistent with that observed in advanced disease6–8. Biomarkers predictive of drug toxicity remain an unmet need. Despite a high-risk population, including approximately half of patients with clinical stage III disease, 88% of patients had planned surgery. Median DFS and OS were not reached, with an encouraging 3-year OS rate of 80%.

MPR was selected as the primary end point for this study to provide reasonable comparison to historical studies of neoadjuvant chemotherapy, in which MPR rates of 15–22% have been reported, rather than single-digit pCR rates9,10. These response rates have recently been substantiated in the randomized chemotherapy arm of CheckMate 816, reporting an MPR rate of 9% and pCR rate of 2%11. Small studies of neoadjuvant nivolumab monotherapy have demonstrated MPR rates of 22–45%12,13. Although MPR rates of 57–83% following neoadjuvant chemoimmunotherapy have recently been reported12,13, the addition of chemotherapy may confound the interpretation of immune predictors. Moreover, the results of these small studies have large confidence intervals. Larger
studies, such as LCMC3 and CheckMate 816, provide more accurate MPR rates following neoadjuvant treatment, with an MPR rate in the tumor post-atezolizumab monotherapy of 20% and in the tumor and lymph nodes post-nivolumab plus chemotherapy of 37%. The ability to select patients for the most effective systemic regimen—single-agent immunotherapy, chemotherapy or chemoinmunotherapy—remains a major unmet clinical need. The phase III IMpower130 study of neoadjuvant atezolizumab and chemotherapy is ongoing.

LCMC3 is also the largest analysis of pre- and post-treatment samples in patients with NSCLC treated with single-agent immunotherapy, enabling the robust study of predictive biomarkers. Consistent with findings in the metastatic setting, MPR was associated with high PD-L1 TPS, but as PD-L1 status was unknown for 19% of patients, this outcome should be interpreted with caution. We show in a rigorous training–testing analysis that multi-lineage immunophenotyping of a pre-treatment peripheral blood sample provides information that may predict the probability of pathological response. Consistent with previous studies of patients with NSCLC treated with PD-L1 blockade, we observed significant expansion of peripheral blood-activated CD8+ T cells in patients with tumors demonstrating MPR. Unexpectedly, we also found significant associations between NK and NK-like T cell markers in both the peripheral blood and tumor tissue and response. Specifically, high pre-treatment levels of NK-like T cells and NK cells, including subsets expressing ILT2/NKG2A, were significantly associated with lack of response, a result verified in two test cohorts. Expression of ILT2, which binds to human leukocyte antigen (HLA)-G, on NK cells and invariant NK T cells contributes to tumor tolerance by reducing the proliferative and cytotoxic activities of these cells. NKG2A is expressed by immature NK cells and binds to HLA-E, the expression of which is increased in various solid tumors. NKG2A can suppress the proliferation of NK cells and NK cell-mediated cytotoxicity. Antibodies directed against both ILT2/HLA-G and NKG2A/HLA-E are being investigated as therapeutic agents.

In our scRNA-seq data, NK cells in tumor tissue showed higher expression of NKG2A and KIRs, including KIR2DL1, on a larger percentage of NK cells in patients with less pathological regression, suggesting that these subsets impair responses to anti-PD-L1. Differential expression of KIR receptors on tumor-infiltrating lymphocytes of patients with NSCLC treated with neoadjuvant nivolumab has been shown to be associated with MPR. ILT2 in tumor tissue was instead predominantly expressed on DCs, macrophages and monocytes and was positively associated with MPR. The two non-T/non-NK cell subsets that we found to positively associate with MPR in the peripheral blood immunophenotyping analysis express ILT2 and the NKG2A-related molecule NKG2D and therefore are possibly of myeloid lineage. ILT2 and PD-L1 transcripts in tumor samples assessed via bulk RNA-seq were significantly associated with pathological regression in non-squamous tumors at baseline and surgery. Notably, we found PD-L1 to be mainly expressed on DCs and common myeloid progenitor cells and to a lesser extent in tumor tissue. Recent literature suggests that ILT2 and PD-L1 are upregulated on DCs following antigen stimulation and may protect activated DCs from CD8+ T cell attack. Thus, our data suggest that not only the adaptive immune system but also the innate immune system in the circulation and tumor tissue play a role in mediating antitumor immune responses to neoadjuvant anti-PD-L1 therapy.

We recognize that interpretation of our predictive biomarker analyses is limited because of the single-arm design of this study. Additional studies are needed to validate the significantly associated cell subsets and further establish the role of peripheral NK cells and NK-like T cells, as well as DCs in tumor tissue, in antitumor responses to immune-checkpoint inhibitors in NSCLC. Following external validation, the value of these cell subsets in predicting outcomes in the clinical practice setting must be determined. Each
IMMUNOME panel subset was limited to ten markers; therefore, cells with markers of interest may overlap between subsets (Supplementary Tables 5, 7 and 9). We also acknowledge as a limitation that MPR (as defined by Pataer) was assessed only on the primary tumor; data on the lymph nodes were exploratory and will be presented elsewhere.

In conclusion, neoadjuvant treatment with single-agent atezolizumab yielded a 20% MPR rate in patients with stage IB–III NSCLC, with no new safety signals and encouraging survival. These data confirm that anti-PD-L1 monotherapy is effective in a subset of patients and begins to address two major unmet needs: understanding which biomarkers are predictive of immunotherapy response and identifying patients who may not need chemotherapy. Our biomarker analyses showed that pre-treatment peripheral blood immune cell profiles may predict MPR in atezolizumab-treated patients with resectable NSCLC. Although confirmatory and functional studies are needed, the insights from this analysis also suggest an important role for the innate immune system in the context of PD-(L)1 inhibition and the potential for new treatment regimens involving agents that modulate ILT2/HLA-G and NKG2A/HLA-E.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-022-01962-5.

Received: 8 March 2022; Accepted: 21 July 2022; Published online: 12 September 2022

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

LCMC study investigators

Jamie E. Chaft1,2,28, Dwight H. Owen3,11, Eric B. Haura16, Ciaran J. McNamee9,10, Saiama N. Waqar17,19, Elaine Shum20,21, Misako Nagasaka22, Marianna Koczywas23, Edward B. Garon12, David J. Finley24, David R. Camidge25, Jennifer W. Carlisle26 and Justin D. Blasberg27

19Alvin J. Siteman Cancer Center, St. Louis, MO, USA. 20New York University Langone Health, New York, NY, USA. 21Perlmutter Comprehensive Cancer Center, New York University, New York, NY, USA. 22Karmanos Cancer Institute, Detroit, MI, USA. 23City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 24Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 25University of Colorado Cancer Center, Aurora, CO, USA. 26Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. 27Yale University School of Medicine, New Haven, CT, USA. A full list of members and their affiliations appear in the Supplementary Information.
METHODS

Study design. LCMC3 was an open-label, single-arm, phase II study (NCT02927301) of atezolizumab administered to patients with NSCLC before curative-intent surgery. The study, performed at 13 sites in the United States (Supplementary Table 1), consisted of two parts: a neoadjuvant phase and an optional adjuvant phase (Extended Data Fig. 1).

Patients were scheduled to receive two doses of atezolizumab, 1,200 mg intravenously, given 3 weeks apart before planned surgical resection. Dose delays, but not modifications, were permitted. Tumors were staged at screening by computed tomography (CT) of the chest, positron emission tomography, brain magnetic resonance imaging and pathological confirmation of nodal involvement when appropriate. Scans were repeated before resection to assess response and confirm surgical eligibility. Tumor, lymph node (when feasible) and whole blood samples were obtained before neoadjuvant atezolizumab and at surgery. Postoperatively, patients were permitted to receive standard-of-care adjuvant chemotherapy+ thoracic radiotherapy. Thereafter, patients with absence of radiographical progression following neoadjuvant atezolizumab and complete resection were permitted to receive adjuvant atezolizumab for up to 12 months. CT scans of the chest were acquired after surgery, then every 3–6 months thereafter for up to 2 years; additional imaging was obtained as clinically indicated.

Patients. Participants were ≥18 years old, had pathologically documented stage IIB–IIIIB NSCLC as per the American Joint Committee on Cancer Staging System (8th edition) and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per RECIST (v.1.1) and an ECOG performance status score 0–1. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Study oversight. LCMC3 was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine; New York University; The Ohio State University; Karmanos Cancer Institute; Brigham and Women’s Hospital and Dana–Farber Cancer Institute; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; UCLA Community Oncology Practice; Dartmouth-Hitchcock Medical Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Winship Cancer Institute, Emory University School of Medicine; and Yale Cancer Center). All patients provided written informed consent.

Outcomes. Clinical data were captured electronically using Medidata Classic Rave (v.2019.2.0). Per protocol, the primary end point was MPR (≥10% viable malignant cells per tumor at resection) and subsequently reviewed by a central pathology committee. Prior analysis (v.2019.2.0). Per protocol, the primary end point was MPR (≥10% viable malignant cells per tumor at resection) and subsequently reviewed by a central pathology committee. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Postoperatively, patients were permitted to receive standard-of-care adjuvant chemotherapy+ thoracic radiotherapy. Thereafter, patients with absence of radiographical progression following neoadjuvant atezolizumab and complete resection were permitted to receive adjuvant atezolizumab for up to 12 months. CT scans of the chest were acquired after surgery, then every 3–6 months thereafter for up to 2 years; additional imaging was obtained as clinically indicated.

Patients. Participants were ≥18 years old, had pathologically documented stage IIB–IIIIB NSCLC as per the American Joint Committee on Cancer Staging System (8th edition) and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per RECIST (v.1.1) and an ECOG performance status score 0–1. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Study oversight. LCMC3 was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine; New York University; The Ohio State University; Karmanos Cancer Institute; Brigham and Women’s Hospital and Dana–Farber Cancer Institute; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; UCLA Community Oncology Practice; Dartmouth-Hitchcock Medical Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Winship Cancer Institute, Emory University School of Medicine; and Yale Cancer Center). All patients provided written informed consent.

Outcomes. Clinical data were captured electronically using Medidata Classic Rave (v.2019.2.0). Per protocol, the primary end point was MPR (≥10% viable malignant cells per tumor at resection) and subsequently reviewed by a central pathology committee. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Postoperatively, patients were permitted to receive standard-of-care adjuvant chemotherapy + thoracic radiotherapy. Thereafter, patients with absence of radiographical progression following neoadjuvant atezolizumab and complete resection were permitted to receive adjuvant atezolizumab for up to 12 months. CT scans of the chest were acquired after surgery, then every 3–6 months thereafter for up to 2 years; additional imaging was obtained as clinically indicated.

Patients. Participants were ≥18 years old, had pathologically documented stage IIB–IIIIB NSCLC as per the American Joint Committee on Cancer Staging System (8th edition) and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per RECIST (v.1.1) and an ECOG performance status score 0–1. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Study oversight. LCMC3 was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine; New York University; The Ohio State University; Karmanos Cancer Institute; Brigham and Women’s Hospital and Dana–Farber Cancer Institute; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; UCLA Community Oncology Practice; Dartmouth-Hitchcock Medical Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Winship Cancer Institute, Emory University School of Medicine; and Yale Cancer Center). All patients provided written informed consent.

Outcomes. Clinical data were captured electronically using Medidata Classic Rave (v.2019.2.0). Per protocol, the primary end point was MPR (≥10% viable malignant cells per tumor at resection) and subsequently reviewed by a central pathology committee. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Postoperatively, patients were permitted to receive standard-of-care adjuvant chemotherapy + thoracic radiotherapy. Thereafter, patients with absence of radiographical progression following neoadjuvant atezolizumab and complete resection were permitted to receive adjuvant atezolizumab for up to 12 months. CT scans of the chest were acquired after surgery, then every 3–6 months thereafter for up to 2 years; additional imaging was obtained as clinically indicated.

Patients. Participants were ≥18 years old, had pathologically documented stage IIB–IIIIB NSCLC as per the American Joint Committee on Cancer Staging System (8th edition) and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per RECIST (v.1.1) and an ECOG performance status score 0–1. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Study oversight. LCMC3 was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine; New York University; The Ohio State University; Karmanos Cancer Institute; Brigham and Women’s Hospital and Dana–Farber Cancer Institute; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; UCLA Community Oncology Practice; Dartmouth-Hitchcock Medical Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Winship Cancer Institute, Emory University School of Medicine; and Yale Cancer Center). All patients provided written informed consent.

Outcomes. Clinical data were captured electronically using Medidata Classic Rave (v.2019.2.0). Per protocol, the primary end point was MPR (≥10% viable malignant cells per tumor at resection) and subsequently reviewed by a central pathology committee. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Postoperatively, patients were permitted to receive standard-of-care adjuvant chemotherapy + thoracic radiotherapy. Thereafter, patients with absence of radiographical progression following neoadjuvant atezolizumab and complete resection were permitted to receive adjuvant atezolizumab for up to 12 months. CT scans of the chest were acquired after surgery, then every 3–6 months thereafter for up to 2 years; additional imaging was obtained as clinically indicated.

Patients. Participants were ≥18 years old, had pathologically documented stage IIB–IIIIB NSCLC as per the American Joint Committee on Cancer Staging System (8th edition) and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per RECIST (v.1.1) and an ECOG performance status score 0–1. The status of any available biomarker was not a condition of enrollment. Exclusion criteria included history of lung cancer in the preceding 3 years, previous treatment with a PD-1/PD-L1 inhibitor, major surgical procedure or severe infection in the preceding 28 d, history of autoimmune disease and history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia or evidence of active pneumonitis on chest CT.

Study oversight. LCMC3 was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine; New York University; The Ohio State University; Karmanos Cancer Institute; Brigham and Women’s Hospital and Dana–Farber Cancer Institute; City of Hope Comprehensive Cancer Center; Moffitt Cancer Center; UCLA Community Oncology Practice; Dartmouth-Hitchcock Medical Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Winship Cancer Institute, Emory University School of Medicine; and Yale Cancer Center). All patients provided written informed consent.
Batch effects due to sequencing data and library preparation kit were removed using the R package limma. After discarding genes not present at 20±5.0 c.p.m. in ≥10% of samples (due to low abundance), 17,729 genes remained for analysis. xCell (v1.3.1) was used to identify enriched cell subsets in pre- and post-treatment samples on the basis of the relative abundance of their transcriptionomes.

scRNA-seq. Fresh tumor samples were collected from patients enrolled after 4 January 2019. In total, 15 surgical samples from six patients with NSCLC and nine with squamous NSCLC were analyzed via scRNA-seq. Briefly, fresh tumor and matched-normal samples were dissociated into single-cell suspensions using the Human Tumor Dissociation kit (Miltenyi Biotec) and gentleMACS Dissociator (Miltenyi Biotec). Erythrocytes were removed using the Red Blood Cell Lysis Solution kit (Miltenyi Biotec). After washing in cold PBS, sample viability (>70%) was confirmed using Trypan blue staining. Viable samples were then loaded onto a Chromium Controller (10X Genomics). Drop-out emulsions were immediately recovered for reverse transcription via a Bio-Rad thermocycler. Single-cell expression libraries were constructed using the Chromium Single Cell 5′ Feature Barcode Library kit (v1.1 (10X Genomics)), the quality of which was assessed using the BioAnalyzer High Sensitivity DNA kit (Agilent). The resulting libraries were then sequenced using NextSeq 500 (Illumina).

Raw sequencing data were aligned to the GRCh38 reference genome using Cell Ranger pipeline (10X Genomics) to generate gene-cell count matrices. Data normalization and integration were performed using the Seurat R package (v.4.0.2). Cells were filtered from the downstream analysis using the following criteria: >900 or >6,000 genes detected and >0.1 fraction of mitochondrial genes. The integrated Seurat object was further scaled by regressing out unique molecular identifier count and the fraction of mitochondrial genes. The optional principal component for dimensionality reduction was determined empirically for each analysis by the drop-off in principal component variance.

Statistical analyses. An MPR rate of ≥15% was selected as evidence of clinical efficacy based on a previous study. To provide 95% power to detect a 10% difference (null hypothesis 5%) at a one-sided significance level of 0.05, we targeted 180 patients for enrollment. Tumors from patients with incomplete surgical resection were considered to not have MP. Patients who did not undergo surgery following neoadjuvant atezolizumab were not evaluable for MP. All atezolizumab-treated patients with NSCLC were included in the safety population. The Kaplan–Meier method was used for the survival analyses, which were performed in the subset of patients in the efficacy population with R0 resection. The data cutoff date was 15 October 2021. Statistical analyses were performed using SAS Proprietary Software (v9.4; SAS Institute), R (v4.1.0, ggpubr2_3.3.5, ggpubr_0.4.0) and R (v4.0.5 (2021-03-31)).

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
Complete de-identified patient data will be available indefinitely within 2 years after the last patient's last survival follow-up visit. Qualified researchers may request access to individual patient-level clinical data through Vivli (data request platform used at the time of this writing) at https://vivli.org/ourmember/roche/. For up-to-date details on Roché's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see https://vivli.org/roche.com/about/sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in the risk of patient re-identification. Requests for the exploratory biomarker data underlying this publication should be directed to LCMC3 Core Study Team@gene.com for consideration. Data from the Genome Reference Consortium Human Build 38 can be accessed at www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/.

Code availability
The custom computer code used to generate the IMMUNOME results reported in this paper can be accessed at https://doi.org/10.5281/zenodo.6811671.

References

Acknowledgements
The authors thank the patients and their families, the study investigators and clinical site staff and the collaborating laboratories for biomarker testing. The authors thank J. Minna, LCMC3 Steering Committee member and consultant. The authors thank R.I. Kitisar and R. Pearson for their contributions to the IMMUNOME analysis. Clinical trial and operations support was provided by E. Brandao, Senior Clinical Trial Leader, M. Rocha, Clinical Program Leader, A. Gopalakrishnan, Senior Biosample Operations Manager and A. Stone, Principal Biosample Operations Manager. The LCMC3 study was funded by Genentech. Medical writing support for the development of the manuscript, under the direction of the authors, was provided by Ashfield MedComms, an Ashfield Health company and was funded by Genentech. F.O. was supported by the Deutsche Forschungsgemeinschaft (OE698/1-1).

Author contributions
The LCMC3 study was conceived by D.P.C. The study protocol was developed by the LCMC3 Steering Committee (B.E.J., D.P.C., J.M.L., M.G.K., P.A.B. and V.W.R.). All authors assisted in data analysis and interpretation, drafted the manuscript (J.E.C., F.O. and D.P.C.) or revised it critically for important intellectual content, approved the final draft and agreed to be accountable for the data reported herein.

Competing interests
J.E.C. serves as an advisor to Genentech/Roche, AstraZeneca/MedImmune, Merck, Bristol Myers Squibb, Flame Biosciences, Janssen Oncology, Guardant Health, Regeneron/Sanofi and Novartis. She reports research funding from Genentech/Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, Novartis and Merck. F.O. reports honoraria from Novartis, serves as an advisor to Epigenomics, Sanofi-Aventis and Decibio and has received travel, accommodations and expenses from Genentech/Roche and research funding (paid to her institution) from Genentech/Roche. M.G.K. reports speaking fees from AstraZeneca and Pfizer, consultant fees from Janssen and in kind support for medical writing from Hofmann La Roche. P.A.B. is on advisory or data safety monitoring boards for Bristol Myers Squibb and Merck and reports membership on the Board of Directors for Verastem, with funding paid to his institution. I.I.W. reports grants and personal fees from Genentech/Roche, Bayer, Bristol Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, GlaxoSmithKline, Guardant Health, Merck, Novartis, Sanofi and Amgen; personal fees from Asuragen, Flame, Daiichi Sankyo, Oncocyte, MSD and Platform Health; and grants from Adaptive, Adaptimmune, EMD Serono, Takeda, Karus, Johnson & Johnson, 4D, Ivance and Akoya, outside of the submitted work. D.J.K. serves as an advisor to AstraZeneca and Genentech/Roche and reports research funding from AADi, Genentech and Revolution Medicine. D.H.O. receives funding (paid to his institution) from Genentech, Merck, Pfizer and Bristol Myers Squibb. Y.T. reports no relationships to disclose. B.E.J. reports consultant fees from Checkpoint Therapeutics, Genentech, Hummingbird Diagnostics and Hengrui Therapeutics. J.M.L. reports grants, consulting fees and honoraria from AstraZeneca, Bristol Myers Squibb, Genentech and Novartis and leadership roles at AstraZeneca, Genentech and Novartis. G.L. reports research funding from Genentech, Innate Pharma, Novartis and Stemline Therapeutics. M.P. reports no relationships to disclose. M.S. reports no relationships to disclose. W.Y.B. reports no relationships to disclose. K.S. is an employee of Genentech and reports stock ownership with Roche. A.N. is an employee of Genentech and reports stock ownership with Roche. A.J. is an employee of...
employee of Genentech and reports stock ownership with Roche. J.G. is an employee of Genentech and reports stock ownership with Roche. S.H. is an employee of Genentech and reports stock ownership with Roche. D.S. is an employee of Genentech and reports stock ownership with Roche. C.R. reports no relationships to disclose. E.T. reports honoraria from Intuitive Surgical. E.B.H. serves in a consulting or advisory role to Amgen, Ellipses Pharma, Janssen Oncology, Janssen Research & Development and Revolution Medicines; reports research funding (paid to his institution) from AstraZeneca, Genentech, Incyte, Janssen, Novartis, Revolution Medicines and Spectrum Pharmaceuticals; and reports patents, royalties or other intellectual property from Protein- Protein Interactions as Biomarkers Patent. C.J.M. reports no relationships to disclose. G.A.P. reports no relationships to disclose. S.N.W. reports research support grants from AbbVie, Ariad Pharmaceuticals, Genentech, Immunomedics, Millennium Pharmaceuticals, Roche, Astellas Pharma, Daiichi Sankyo, Callinex Pearl, Verastem, GlaxoSmithKline/GSK, Janssen Research & Development, Elevation Oncology, Genentech, Lexo Oncology, Takeda Pharmaceuticals Company Limited and the SWOG Clinical Trials Partnership; has received honoraria from the American Society of Clinical Oncology; and serves as Chair of the Data Safety Monitoring Board for the Hoosier Cancer Research Network. V.W.R. is a member of the Data Safety and Monitoring Committee for the MARS2 trial (UK) and serves as Co-Chair of the National Cancer Institute Thoracic Staging Malignancy Committee. She reports funding (paid to her institution) from Genentech. D.P.C. serves in a consultant or advisory role to AbbVie, Agenus, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech/Roche, Helsinn Healthcare, Incyte, Invitasa, Inovio Pharmaceuticals, Janssen, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, prIME Oncology and Takeda and research funding from Bristol Myers Squibb and Genentech.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-022-01962-5.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-022-01962-5.
Correspondence and requests for materials should be addressed to David P. Carbone.
Peer review information Nature Medicine thanks Caicun Zhou and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling editors: Saheli Sadanand and Joao Monteiro, in collaboration with the Nature Medicine team.
Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Study design. *Mandatory. CT, computed tomography; NSCLC, non-small cell lung cancer; PET, positron emission tomography; q3m, every 3 months; SOC, standard of care.
Extended Data Fig. 2 | CONSORT diagram for the various biomarker analyses. aTwo patients were determined to have hemangioma and solitary fibrous tumor at resection despite initial pathology consistent with NSCLC. Includes 1 EGFR-positive patient. bThe reasons were as follows: clinical progression (n = 3), physician did not want to delay patient surgery (n = 1), physician did not consider the patient a good surgical candidate (n = 1), and physician discontinued patient from the study because of an adverse event (n = 1). cOne patient was determined to have preexisting congestive heart failure, 1 declined surgery, and 1 was lost to follow-up. dEighty patients provided a total of 98 samples for the bulk RNA-seq analyses (54 at baseline and 44 at surgery). ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ES, exome sequencing; MPR, major pathologic response; NSCLC, non-small cell lung cancer; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; RNA-seq, ribonucleic acid sequencing; scRNA-seq, single-cell ribonucleic acid sequencing; TMB, tumor mutational burden.
Extended Data Fig. 3 | Relationship between MPR, histology, and TMB. (a) Pathologic response by mutation status (n = 85). TMB showed a positive but not significant trend with pathologic response in non-squamous (R = 0.28; P = 0.05) and squamous (R = 0.23; P = 0.22) tumors. KEAP1 mutations were not significantly associated with pathologic response in either non-squamous (P = 0.46) or squamous tumors (P = 0.98). KRAS and STK11 mutations were found only in non-squamous tumors, where mutations in STK11 were found to significantly associate with pathologic response (P = 0.01), and mutations in KRAS were not (P = 0.87). (b) Pathologic response by the overlapping mutational status of KRAS and STK11 in patients with non-squamous NSCLC (n = 78). The maximum and minimum values of the boxes denote the IQR. The line within the IQR denotes the median. The extremities of the dashed lines represent the 5th to 95th percentiles. *TMB was only determined for the subset of patients with ES data from baseline and/or surgery with tumor purity ≥15%. P values for TMB in Panel a were determined via linear correlation test (Pearson). P values for mutation status in Panels a and b were determined via two-sided Wilcoxon rank sum test. ES, exome sequencing; IQR, interquartile range; KEAP1, Kelch-like ECH-associated protein 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; MPR, major pathologic response; NS, non-significant; NSCLC, non-small cell lung cancer; STK11, serine/threonine kinase 11; TMB, tumor mutational burden.
Extended Data Fig. 4 | DFS (a) and OS (b) by disease stage, use of adjuvant atezolizumab, and lymph node status (n = 143). The MPR rate in patients who did and did not receive adjuvant atezolizumab was 41% (22/54) and 8% (7/89), respectively. DFS, disease-free survival; OS, overall survival.
Extended Data Fig. 5 | See next page for caption.
Extended Data Fig. 5 | Gating strategy for the IMMUNOME tubes described in Supplementary Table 5. (a) Tubes 1-11 were gated on the basis of CD45 and side scatter. The immune cell populations of interest were those falling within the region ‘lymphocytes,’ which was defined by CD45<sup>hi</sup>, a low side scatter, and a lymphosum (CD3<sup>+</sup> CD19<sup>+</sup> CD56<sup>-</sup> CD16<sup>+</sup>) totaling 95%–100%, with <5% myeloid contamination. Tube 1 (lymphosum) contained lymphosum markers, as well as myeloid markers (CD13/CD14). The gate established for Tube 1 was applied to Tubes 2-11. (b) Tube 12 (myeloid cells) used LIN (CD3<sup>+</sup> CD19<sup>+</sup> CD56<sup>-</sup>) as an exclusion gate. Plots were gated using three different strategies: LIN<sup>-</sup> total, LIN<sup>-</sup> CD11b<sup>+</sup>, and LIN<sup>-</sup> CD33<sup>-</sup>. (c) Tube 13 (senescent cells) used both lymphocyte and sequential gating to find the immune cell population of interest. Lymphocyte gating isolated CD28<sup>-</sup> CD16<sup>-</sup> CD56<sup>-</sup> CD3<sup>+</sup> cells, which were sequentially gated on CD57. Events falling with the CD57<sup>-</sup> region were considered senescent cells. Senescent cells were further classified into subsets defined by positivity and negativity for CD4, CD8, KLRG1, and CD127. (d) Tube 14 (dendritic cells) used LIN as an exclusion gate. Plots were gated using three different strategies: LIN<sup>-</sup> total, LIN<sup>-</sup> CD1c<sup>+</sup>, and LIN<sup>-</sup> CD14<sup>+</sup>. CD, cluster of differentiation; KLRG1, killer cell lectin-like receptor subfamily G member 1; LIN, lineage.
Extended Data Fig. 6 | ROC curves for test set 1 (n = 54), which considered only peripheral blood IMMUNOME, as well as for test set 1 in combination with histology (non-squamous [n = 32] vs. squamous [n = 22]), nodal status (N1/N2 [n = 35] vs. N0 [n = 19]), PD-L1 expression (n = 54), sex (female [n = 26] vs. male [n = 28]), or smoking status/history (never [n = 6] vs. current/former [n = 48]). The dashed y = x line, which represents random assignment, is included for reference. *Immunophenotyping via flow cytometry. PD-L1, programmed death-ligand 1; ROC, receiver operating characteristic.
Extended Data Fig. 7 | Immune cell subsets with significant (two-sided $p < 0.05$) changes in abundance before (baseline) and after (at surgery) neoadjuvant treatment with atezolizumab. No adjustment was made for multiplicity. A, CD45+ CD62L+ CD27+ CD56/16- CD45RO+ CCR7- CD45RA- CD4- CD3+ CD8+ ($p = 0.0081$); B, CD45+ CD33+ HLA-DR+ CD124- CD14+ CD11b+ CD66b- CD16- CD33+ CD15+ ($p = 0.0042$); C, CD45+ HLA-DR+ CD124- CD14+ CD11b+ CD66b- CD16- CD33+ CD15+ ($p = 0.0042$); D, CD45+ CD94+ NKG2D+ CD3+ CD56+ CD117- NKG2A- CD127+ CD161- CD16+ ($p = 0.0036$); E, CD45+ LIN+ HLA-DR+ CD33+ CD16+ CD11b+ CD15+ ($p = 0.0092$); F, CD45+ HLA-DR+ CD69+ CD19+ CD56+ CD16+ CD134+ CD4+ CD3+ CD8+ ($p = 0.0079$); G, CD45+ CD11b+ HLA-DR+ CD124- CD14+ CD11b+ CD66b- CD16- CD33+ CD15+ ($p = 0.0157$); H, CD45+ γ/δ α/β CD19+ CD56+ CD16- CD13/14+ CD4+ CD3+ CD8- ($p = 0.0113$); I, CD45+ HLA-DR+ CD69+ CD3+ KIR3DL1- KIR2DL2- NKG2A- CD56+ KIR2DL1- CD16+ ($p < 0.0001$); J, CD45+ CD107a/b+ CD59c+ CD3+ KIR3DL1+ KIR2DL2+ Nkp80+ CD56+ KIR2DL1+ CD16+ ($p = 0.0025$); K, CD45+ HLA-DR+ CD69+ CD19+ CD56+ CD16+ CD134+ CD4- CD3+ CD8- ($p = 0.0004$); L, CD45+ CD16+ CD336- CD3- CD244+ CD335+ NKG2D+ CD56- CD161+ CD37+ ($p = 0.0002$); M, CD45+ γ/δ α/β CD19+ CD56+ CD16+ CD13/14+ CD4- CD3+ CD8+ ($p = 0.0191$); N, CD45+ HLA-DR+ CD69+ CD3+ KIR3DL1- KIR2DL2+ NKG2A- CD56+ KIR2DL1- CD16+ ($p = 0.0307$); O, CD45+ CD62L- CD27+ CD56/16+ CD45RO- CCR7- CD45RA- CD4- CD3+ CD8+ ($p = 0.0400$); P, CD45+ CD94+ NKG2D- CD3+ CD56+ CD117- NKG2A- CD127+ CD161+ CD16+ ($p = 0.0480$); Q, CD45+ HLA-DR+ CD69+ CD3+ KIR3DL1- KIR2DL2+ NKG2A- CD56- KIR2DL1+ CD16+ ($p = 0.0014$); R, CD45+ LIN+ HLA-DR- CD33+ CD16+ CD11b+ CD15+ ($p = 0.0030$). *Pre-treatment predictor of MPR. LIN included CD19, CD3, and CD56. NKG2A is also known as CD159a, NKG2D as CD314 and KLRK1, KIR2DL1 as CD158a, KIR2DL2 as CD158b, CD335 as Nkp46, and CD337 as Nkp30. γ/δ, α/β chains of the T cell receptor; γ/δ, α/β chains of the T cell receptor; CCR7, C-C motif chemokine receptor 7; CD, cluster of differentiation; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin-like receptor; KLR, killer cell lectin-like receptor; LIN, lineage; MPR, major pathologic response; NK, natural killer; NKG2, natural killer group protein 2.
Extended Data Fig. 8 | Association between gene expression in NK cells and the percentage of viable tumor cells. The expression of different NK cell surface receptors was determined by scRNA-seq. Tumor samples collected at resection were classified into 3 groups of 5 samples each based on the percentage of viable tumor cells by pathologic analysis: low (≤25% viable tumor cells), middle (26%–50%), and high (>50%). UMAP plots of NK cells show normalized expression of several receptors in the 3 groups of viable tumor cell numbers. NK cells were down-sampled to have the same number of cells in each group. ILT2 is also known as LILRB1, ILT4 as LILRB2, NKG2A as CD159a, NKG2D as CD314 and KLRK1, KIR2DL1 as CD158a, KIR2DL3 as CD158b, KIR2DL4 as CD158d, KIR3DL1 as CD158e1, and KIR3DL2 as CD158k. CD, cluster of differentiation; ILT, immunoglobulin-like transcript; KIR, killer cell immunoglobulin-like receptor; KLR, killer cell lectin-like receptor; LILRB, leukocyte immunoglobulin-like receptor subfamily B; max, maximum; min, minimum; NK, natural killer; NKG2, natural killer group protein 2; scRNA-seq, single-cell ribonucleic acid sequencing; UMAP, uniform manifold approximation and projection.
**Extended Data Fig. 9** | Association of (a) ILT2 and (b) PD-L1 transcripts with the cell type enrichment scores of specific immune cell subsets derived from bulk RNA-seq at baseline and at surgery by tumor histology. Relative immune cell abundance was estimated from RNA-seq data using the cell type enrichment analysis tool xCell and correlated with the abundance (log$_2$ cpm) of ILT2 or PD-L1. Results are shown for all baseline and surgical samples with RNA-Seq, split by histology. A positive correlation coefficient (blue) indicates samples with an increased abundance of a given immune cell signature also having an increased abundance of either ILT2 or PD-L1. Asterisks indicate significant correlations (unadjusted Pearson correlation two-sided $P < 0.05$). ILT2 is also known as LILRB1 and PD-L1 as CD274. CD, cluster of differentiation; cpm, counts per million reads mapped; DC, dendritic cell; ILT2, immunoglobulin-like transcript 2; LILRB, leukocyte immunoglobulin-like receptor subfamily B; NK, natural killer; PD-L1, programmed death-ligand 1; RNA-seq, ribonucleic acid sequencing.
**Extended Data Fig. 10 | Association of ILT2 and PD-L1 transcripts with pathologic response at baseline and at surgery by tumor histology.** Expression values for each transcript are presented as log₂ (cpm + 1). Two-sided $P$-values for Pearson (R) and Spearman ($\rho$ [Rho]) correlation are shown. The grey band represents the 95% confidence interval for the linear regression line. No adjustment was made for multiplicity. Of the 54 patients at baseline with RNA-seq data, 52 also had pathologic response data available. ILT2 is also known as LILRB1 and PD-L1 as CD274. CD, cluster of differentiation; cpm, counts per million reads mapped; ILT2, immunoglobulin-like transcript 2; LILR1, leukocyte immunoglobulin-like receptor 1; MPR, major pathologic response; PD-L1, programmed death-ligand 1; RNA-seq, ribonucleic acid sequencing.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐ The statistical test(s) used AND whether they are one- or two-sided

*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*

☐ A description of all covariates tested

☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted

*Give P values as exact values whenever suitable.*

☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

*Our web collection on statistics for biologists contains articles on many of the points above.*

Software and code

Policy information about availability of computer code

Data collection

| EDC (electronic data capture), Medidata Classic Rave * v2019.2.0 |
| Nextera® Rapid Capture Enrichment (Illumina); HiSeq™ 2500, HiSeq™ v4, NovaSeq™, HiSeq™ X, or HiSeq™ 4000 (Illumina) |
| Navios Cytometer (Beckman Coulter Life Sciences) |

Data analysis

| Seurat R v4.0.2 and v4.1.0, ggplot2_3.3.5, and ggpubr_0.4.0 |
| GSNIAP v2013-10-10, R v4.0.5 (2021-03-31), xCell (v1.3), Strelka (v1.0.14), and Lofreq (v2.1.2), Ensembl Variant Effect Predictor (v77) |
| Navios Analysis Software version 2.1 (Beckman Coulter Life Sciences) |

The custom code used to generate the IMMUNOME results reported in this paper can be accessed at https://doi.org/10.5281/zenodo.6811671.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Complete de-identified patient data will be available indefinitely within 2 years after the last patient’s last Survival Follow-Up visit. Qualified researchers may request access to individual patient-level clinical data through Vivli [data request platform used at the time of this writing]: https://vivli.org/ourmember/roche/.

For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see https://go.roche.com/data_sharing.

Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in the risk of patient re-identification.

Requests for the exploratory biomarker data underlying this publication should be directed to LCMC3_Core_Study_Team@gene.com for consideration.

Data from Genome Reference Consortium Human Build 38 can be accessed at www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-fist.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

An MPR rate of ≥15% was selected as evidence of clinical efficacy based on a prior study (Chait, JE, et al. J Thorac Oncol. 11, 537-544 [2016]). To provide 95% power to detect a 10% difference (null hypothesis 5%) at a one-sided significance level of 0.05, we targeted 180 patients for enrollment.

Data exclusions

For the clinical data analyses, patients whose tumors had EGFR or ALK alterations were excluded per protocol. At the time that the protocol for the LCMC3 study was being drafted, data on the effect of EGFR mutations/ALK alterations on immune checkpoint inhibitors were only beginning to emerge. In addition, all of those data derived from the metastatic setting. The effect of PD-(L)1 therapy on early-stage disease in patients with EGFR mutations had not yet been studied.

For the IMMUNOMINE analyses, marker combinations detected in <50% of patients were excluded for two reasons. First, the difference in I-index that was used for feature pre-selection may have been difficult to approximate in cases where we had two orthogonal immunomes. In such cases, the index would be close to 1, and as we measured changes in the index with a single feature removed, numerical issues would have possibly been introduced. Second, in the model selection procedure, we only used presence/absence for features with low prevalence. Inclusion of features present in only a small fraction of individuals would have allowed for fitting pathological models in which a feature would be an indicator in only a few samples. By enforcing the median as non-zero, a given a feature is expected to be an indicator in at least half of the samples.

Cells with impossible cell surface marker combinations (e.g., both CD3+ and CD19+) were also excluded.

Replication

IMMUNOMINE analyses were performed independently in a CLIA-certified clinical laboratory environment. The high-quality laboratory standards included daily flow cytometer calibrations and weekly calibrations across the 8 separate flow cytometers. Technical replicates were therefore not needed. A validated dry down cocktail tube (DURA Innovations) and automated pipetting were used. Every 6 months, a bias evaluation is performed on the same cells on all instruments to confirm instrument-to-instrument reproducibility and bias. We also employed a 14-tube panel with repetitions of markers in several tubes to further ensure reproducibility.

Randomization

None (single-arm study).

Blinding

None (open-label study).

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Human research participants

Policy information about studies involving human research participants

Population characteristics

Participants were ≥18 years old, had pathologically documented stage IB–IIIB NSCLC per the American Joint Committee on Cancer Staging System (8th edition), and were deemed surgically resectable and functionally operable by the treating physicians. Patients had disease that was measurable per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) and an Eastern Cooperative Oncology Group performance status score 0–1.

Demographic characteristics are presented in Table 1. During the building of the IMMUNOME-based predictive model for MPR, gender, smoking status/history, tumor histology, nodal status, and PD-L1 expression were not identified as covariates. The AUC values for models based on IMMUNOME data only or IMMUNOME data plus one clinical variable are presented in Table S6.

Recruitment

The LCMC3 study was conducted at academic institutions throughout the US. Each site implemented screening protocols to identify and offer enrollment to patients with medically operable and technically resectable NSCLC in thoracic surgery and medical oncology clinics. Given the neoadjuvant nature of the study, most patients were enrolled prior to knowledge of predictive biomarkers utilized in more advanced disease stages, making any enrollment selection bias unlikely. As shown in Table 1, the smoking status, histology, and PD-L1 expression profile of this study population parallel that of a typical population of patients with NSCLC. In review of the data, we did not appreciate any enrollment biases or imbalances that would have impacted the study results.

Ethics oversight

The study was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each participating site (Washington University School of Medicine, St. Louis, MO; New York University, New York, NY; The Ohio State University, Columbus, OH; Karmanos Cancer Institute, Detroit, MI; Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA; City of Hope Comprehensive Cancer Center, Duarte, CA; Moffitt Cancer Center, Tampa, FL; UCLA Community Oncology Practice, Los Angeles, CA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; University of Colorado Cancer Center, Denver, CO; Memorial Sloan-Kettering Cancer Center, New York, NY; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; and Yale Cancer Center, New Haven, CT). All patients provided written informed consent.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

NCT02927301

Study protocol

The study protocol is available at: https://www.clinicaltrials.gov/ct2/show/study/NCT02927301.

Data collection

The study was performed at 13 sites in the United States, specifically Washington University School of Medicine, St. Louis, MO; New York University, New York, NY; The Ohio State University, Columbus, OH; Karmanos Cancer Institute, Detroit, MI; Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA; City of Hope Comprehensive Cancer Center, Duarte, CA; Moffitt Cancer Center, Tampa, FL; UCLA Community Oncology Practice, Los Angeles, CA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; University of Colorado Cancer Center, Denver, CO; Memorial Sloan-Kettering Cancer Center, New York, NY; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; and Yale Cancer Center, New Haven, CT. Patients were enrolled between April 20, 2017, and February 3, 2020.

Outcomes

The primary endpoint was major pathologic response (MPR; ≤10% viable malignant cells per local pathology assessment) in the primary tumor at resection. MPR was assessed locally per study-specific pathology training and standard operating procedures and subsequently reviewed by a central pathology committee.

Secondary endpoints included investigator-assessed objective response rate by RECIST, pathologic complete response, pathologic response by PD-L1 expression and tumor mutational burden, and safety (per Common Terminology Criteria for Adverse Events, v4.0). PD-L1 status was centrally determined by immunohistochemistry using the DAKO PD L1 (22C3) assay.

Exploratory endpoints for patients with an MPR assessment included disease-free survival (time from complete resection to disease
Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation
A total of 6 mL of peripheral whole blood was collected in K3 EDTA tubes, which were inverted 8–10 times and shipped at ambient temperature (15–25°C).

Instrument
Navios Cytometer (Beckman Coulter Life Sciences)

Software
Navios Analysis Software version 2.1 (Beckman Coulter Life Sciences)

Cell population abundance
Sequential gating was utilized to ensure that the correct population of cells was analyzed. Viable cells (debris gate), side scatter vs. forward scatter, and CD45 vs. side scatter were used to identify lymphocytes. The first tube of the panel (Lymphosum) was used to enumerate T cell, B cell and NK cell fractions within the lymphocyte gate, totaling 95-100% with less than 5% myeloid contamination (CD13/CD14) to verify that the markers were used on the correct cell populations. Post-sort fractions were not analyzed.

Gating strategy
Plots were gated using three different strategies: LIN= total, LIN− CD11b+, and LIN− CD33+. Tube 13 (senescent cells) used both lymphocyte and sequential gating to find the immune cell population of interest. Lymphocyte gating isolated CD28− CD16− CD56− CD3+ cells, which were sequentially gated on CD57. Events falling with the CD57+ region were considered senescent cells. Senescent cells were further classified into subsets defined by positivity and negativity for CD4, CD8, KLRG1, and CD127. Tube 14 (dendritic cells) used LIN as an exclusion gate. Plots were gated using three different strategies: LIN− total, LIN− CD11c+, and LIN− CD141+.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.